HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FERRIPROX safely and effectively. See full prescribing information for FERRIPROX. FERRIPROX® (deferiprone) tablets, for oral use Initial U.S. Approval: 2011 WARNING: AGRANULOCYTOSIS/NEUTROPENIA See full prescribing information for complete boxed warning. INDICATIONS AND USAGE FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. (1) Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival. (1) Limitation of Use • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias. (1) DOSAGE AND ADMINISTRATION • 25 mg/kg to 33 mg/kg body weight, orally, three times per day, for a total
Visit the Superficial Siderosis Pateint Registry. Open to patients, caregivers, and researchers worldwide. This registry offers you a chance to participate in research surveys and trial announcements.
Visit the official SSRA Gear store. The proceeds of every purchase helps fund the Superficial Siderosis Research Alliance research grant, education, and awareness programs.
Hearing Impaired 5PK
PLEASE VOTE WEEKLY
BLOG: Superficial Siderosis Research Alliance
SUPERFICIAL SIDEROSIS RESEARCH ALLIANCE